Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Huajun Yu, Yingbao Huang, Lifang Chen, Liuzhi Shi, Yunjun Yang & Weizhi Xia. (2021) Assessment of Computed Tomography-Defined Muscle and Adipose Tissue Features in Relation to Length of Hospital Stay and Recurrence of Hypertriglyceridemic Pancreatitis. International Journal of General Medicine 14, pages 1709-1717.
Read now
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
Read now
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2015) Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 14:9, pages 1481-1493.
Read now
Read now
Aris P Agouridis, Devaki R Nair & Dimitri P Mikhailidis. (2015) Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 851-855.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Haralampos Milionis. (2014) Combining a statin with a fibrate versus fibrate monotherapy: efficacious but safe?. Expert Opinion on Drug Safety 13:3, pages 267-269.
Read now
Read now
Hye Duck Choi & Wan Gyoon Shin. (2014) Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis. Current Medical Research and Opinion 30:1, pages 1-10.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Aris P Agouridis, Theodosios D Filippatos, Vasilios Tsimihodimos & Moses S Elisaf. (2011) Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Review of Cardiovascular Therapy 9:3, pages 355-366.
Read now
Read now
Elisavet Moutzouri, Anastazia Kei, Moses S Elisaf & Haralampos J Milionis. (2010) Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular Health and Risk Management 6, pages 525-539.
Read now
Read now
Joe D Strain, Debra K Farver & James R Clem. (2010) A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy. Clinical Pharmacology: Advances and Applications 2, pages 95-104.
Read now
Read now
Terry A Jacobson, Peter H Jones & Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, pages 627-649.
Read now
Read now
Susan M Schima, Stephanie R Maciejewski, Daniel E Hilleman, Mark A Williams & Syed M Mohiuddin. (2010) Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid. Expert Opinion on Pharmacotherapy 11:5, pages 731-738.
Read now
Read now
Articles from other publishers (29)
Li‐Nien Chien, Yun‐I Chou, Yuan‐Jen Tsai, Li‐Chin Sung, Hung‐Yi Liu, Meng‐Yin Lin, Tsung‐Jen Wang & I‐Chan Lin. (2023) Association of lipid‐lowering agent use and dry eye disease: A nationwide matched case–control study in Taiwan, 2002–2016. Acta Ophthalmologica 101:7, pages 729-736.
Crossref
Crossref
Charlotte C.J.R. Michielsen, Roland W.J. Hangelbroek, Marjolijn C.E. Bragt, Elwin R. Verheij, Suzan Wopereis, Ronald P. Mensink & Lydia A. Afman. (2021) Comparative Analysis of the Effects of Fish Oil and Fenofibrate on Plasma Metabolomic Profiles in Overweight and Obese Individuals. Molecular Nutrition & Food Research 66:2.
Crossref
Crossref
Emese Sipos, Tamás Csatári, Adrienn Kazsoki, Attila Gergely, Enikő Bitay, Zoltán-István Szabó & Romána Zelkó. (2020) Preparation and Characterization of Fenofibrate-Loaded PVP Electrospun Microfibrous Sheets. Pharmaceutics 12:7, pages 612.
Crossref
Crossref
Eleni Pappa, Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2019) Emerging Fixed-Dose Combination Treatments for Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 24:4, pages 315-322.
Crossref
Crossref
Arrigo F. G. Cicero, Federica Fogacci, Marilisa Bove, Fulvio Ventura, Marina Giovannini & Claudio Borghi. (2018) Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. High Blood Pressure & Cardiovascular Prevention 25:4, pages 355-359.
Crossref
Crossref
Saranya Ravi, Traci Parry, Monte Willis, Pamela Lockyer, Cam Patterson, James Bain, Robert Stevens, Olga Ilkayeva, Christopher Newgard & Jonathan Schisler. (2018) Adverse Effects of Fenofibrate in Mice Deficient in the Protein Quality Control Regulator, CHIP. Journal of Cardiovascular Development and Disease 5:3, pages 43.
Crossref
Crossref
Amanda J Unsworth, Gagan D Flora & Jonathan M Gibbins. (2018) Non-genomic effects of nuclear receptors: insights from the anucleate platelet. Cardiovascular Research 114:5, pages 645-655.
Crossref
Crossref
Theodosios D. Filippatos, Anastazia Kei, Christos V. Rizos & Moses S. Elisaf. (2017) Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Journal of Cardiovascular Pharmacology and Therapeutics 23:1, pages 3-12.
Crossref
Crossref
Oscar Molins-Molina, Roger Bresolí-Obach, Guillermo Garcia-Lainez, Inmaculada Andreu, Santi Nonell, Miguel A. Miranda & M. Consuelo Jiménez. (2017)
Singlet oxygen production and
in vitro
phototoxicity studies on fenofibrate, mycophenolate mofetil, trifusal, and their active metabolites
. Journal of Physical Organic Chemistry 30:9, pages e3722.
Crossref
Crossref
Tracey G. Simon, Kathleen E. Corey, Raymond T. Chung & Robert Giugliano. (2016) Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Digestive Diseases and Sciences 61:12, pages 3425-3435.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
285
315
.
Lori A. Gordon, Christine Y. Malati, Colleen Hadigan, Mary McLaughlin, Raul M. Alfaro, Mónica M. Calderón, Joseph A. Kovacs & Scott R. Penzak. (2016) Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:1, pages 49-56.
Crossref
Crossref
Abid Mehmood Yousaf, Dong Wuk Kim, Jin Ki Kim, Jong Oh Kim, Chul Soon Yong & Han-Gon Choi. (2015) Novel fenofibrate-loaded gelatin microcapsules with enhanced solubility and excellent flowability: Preparation and physicochemical characterization. Powder Technology 275, pages 257-262.
Crossref
Crossref
A. Sahebkar & G. F. Watts. (2014) Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster. Diabetes, Obesity and Metabolism 16:9, pages 780-792.
Crossref
Crossref
Maxwell P Treacy & Tara P Hurst. (2012) The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy. BMC Ophthalmology 12:1.
Crossref
Crossref
M.T. Bergoglio, S. Veses Martín, E. Solá Izquierdo & A. Hernández Mijares. (2012) Paciente varón de 56 años con múltiples factores de riesgo cardiovascular. Medicine - Programa de Formación Médica Continuada Acreditado 11:19, pages 1186.e1-1186.e5.
Crossref
Crossref
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Byounghoon Hwang, Pengfei Wu & Robert A. Harris. (2012) Additive effects of clofibric acid and pyruvate dehydrogenase kinase isoenzyme?4 (PDK4) deficiency on hepatic steatosis in mice fed a high saturated fat diet. FEBS Journal 279:10, pages 1883-1893.
Crossref
Crossref
Ji-Yin Zhou & Shi-Wen Zhou. (2011) Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver. Fitoterapia 82:2, pages 184-189.
Crossref
Crossref
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, pages 352-358.
Crossref
Crossref
Lily P.H. Yang & Gillian M. Keating. (2009) Fenofibric Acid. American Journal Cardiovascular Drugs 9:6, pages 401-409.
Crossref
Crossref
. (2009) Current World Literature. Current Opinion in Lipidology 20:6, pages 512-519.
Crossref
Crossref
Catherine Fiévet & Bart Staels. (2009) Combination therapy of statins and fibrates in the management of cardiovascular risk. Current Opinion in Lipidology 20:6, pages 505-511.
Crossref
Crossref
Samer O. Abdul-Hay, Praneeth Edirisinghe & Gregory R. J. Thatcher. (2009) Selective modulation of amyloid-β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels. Journal of Neurochemistry 111:3, pages 683-695.
Crossref
Crossref
Vito Iacobazzi, Paolo Convertini, Vittoria Infantino, Pasquale Scarcia, Simona Todisco & Ferdinando Palmieri. (2009) Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochemical and Biophysical Research Communications 388:4, pages 643-647.
Crossref
Crossref
Andrew D. Patterson, Ondřej Slanař, Kristopher W. Krausz, Fei Li, Constance C. Höfer, František Perlík, Frank J. Gonzalez & Jeffrey R. Idle. (2009) Human Urinary Metabolomic Profile of PPARα Induced Fatty Acid β-Oxidation. Journal of Proteome Research 8:9, pages 4293-4300.
Crossref
Crossref
Anthony S Wierzbicki. (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology 24:4, pages 372-379.
Crossref
Crossref
Shridhar Hegde & Michelle Schmidt. 2009. Annual Reports in Medicinal Chemistry Volume 44. Annual Reports in Medicinal Chemistry Volume 44
577
632
.